R Squared’s Oric Pharmaceuticals ORIC Stock Holding History

R Squared’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,800	Closed	-$14.5K	–	1127
2024 Q4	$14.5K	Buy	+1,800	New	+$16.5K	0.01%	1026

Other funds holding ORIC

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

R Squared's ORIC Position: Q1 2025 in Review

R Squared sold out of Oric Pharmaceuticals (ORIC) in Q1 2025, closing a stake of 1,800 shares — an estimated $14.5K sold.

R Squared first reported a position in ORIC in Q4 2024 and held it in 1 quarter. The position peaked at $14.5K in Q4 2024. 143 funds tracked by Wall St. Rank hold ORIC as of Q1 2025.

R Squared reported no remaining Oric Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,800 Oric Pharmaceuticals shares in Q1 2025, an estimated $14.5K.
R Squared first reported a position in Oric Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Oric Pharmaceuticals position peaked at $14.5K in Q4 2024.
143 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.